SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Drug Development
SARS-CoV-2 Causes Heart Damage in 20% of People with Mild or No COVID-19 Symptoms
COVID-19 is a cardiac condition as much as it is a pulmonary or respiratory disease. This knowledge is so recent that it often is overlooked by non-cardiologists, according to physicians speaking at Demy-Colton Virtual Salon, “COVID-19: Surprising Cardiac Findings & Concern about the Potential Impact.”
November 23, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance.
November 19, 2020
 · 
3 min read
 · 
Gail Dutton
Photo courtesy of OncoMyx.
Business
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential
Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.
November 17, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Mouse Seeking Elephant: Innovators Address Unmet Needs in Biotech and Analytics
The 2020 Virtual Texas Life Science Forum, sponsored by BioHouston November 10-12, showcased dozens of innovative, early stage companies seeking partners to reach the next level.
November 16, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
NECI’s Digital Stack Helps Moderna Create its COVID-19 Vaccine in Record Time
Integrating digital tools for manufacturing process development, control and data analytics brings data together in ways that enhance visibility system-wide.
November 12, 2020
 · 
4 min read
 · 
Gail Dutton
Pictured: Red and white Lilly sign on building/Mic
Job Trends
Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
Jeff Dage, Ph.D., senior research adviser at Eli Lilly and Company, presented the case for P-tau in blood as an accurate biomarker.
November 11, 2020
 · 
5 min read
 · 
Gail Dutton
Jeremy Levin, chairman of the global Biotechnology
Business
BIO Chairman: FDA Vaccine Reviews Too Complex and Costly for States to Replicate
Several states have pledged to review COVID-19 vaccines themselves, after FDA emergency use authorizations, to ensure safety and efficacy. A robust review, however, is unlikely.
November 10, 2020
 · 
4 min read
 · 
Gail Dutton
IntraBio Expands Niemann-Pick Trial to ID Neuroprotective, Disease-Modifying Effects
IntraBio lauched a Phase II expansion study for IB1001 (N-Acetyl-L-Leucine) soon after announcing positive results from the initial “parent” multinational trials for Niemann-Pick disease Type C (NPC).
November 9, 2020
 · 
4 min read
 · 
Gail Dutton
Bioelectric Medicine Ready for Prime Time as Companies Advance Therapies
Bioelectric medicine is coming into its own as a combination or stand-alone therapy for a growing cohort of conditions.
November 9, 2020
 · 
1 min read
 · 
Gail Dutton
Business
SPACs Soar as Fast, Hassle-Free IPO Alternatives for Biotech Companies
Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.
November 5, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Bringing Flexion’s OA Gene Therapy to Market Starts with Cost and Benefits in Mind
As more and more gene therapies are approved, the elements that determine their success depend, increasingly, on the business decisions made early on.
November 5, 2020
 · 
4 min read
 · 
Gail Dutton
Bio NC
How COVID-19 is Catalyzing a Better, More Efficient Biopharma Environment
The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.
November 4, 2020
 · 
4 min read
 · 
Gail Dutton
Photo courtesy of Icosavax.
Business
Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing
BioSpace caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411.
November 2, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
COVID-19 is 6-Fold More Prevalent than Reported Incidents, German Study Says
A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.
October 30, 2020
 · 
4 min read
 · 
Gail Dutton
Fabry disease is caused due to buildup of globotri
Business
BIO-Europe® Digital: Kidney Disease Therapeutics on Cusp of Transformative Innovation
Kidney disease hasn’t been an area of vibrant transformation, but it is emerging as a promising and area for diagnostic and therapeutic investigation following an explosion of foundational technologies in recent years, according to speakers at BIO-Europe® Digital, held virtually October 26-29.
October 28, 2020
 · 
4 min read
 · 
Gail Dutton
Load More